OMS
MCID: OTT002
MIFTS: 78

Otitis Media (OMS)

Categories: Ear diseases, Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Otitis Media

MalaCards integrated aliases for Otitis Media:

Name: Otitis Media 57 11 73 28 53 5 2 43 14 16 71 75 33
Opsoclonus-Myoclonus Syndrome 19 58 53 5 16 71
Otitis Media, Susceptibility to 57 28 12 5
Oms 57 19 58 73
Kinsbourne Syndrome 19 58 71
Paraneoplastic Opsoclonus-Myoclonus-Ataxia Syndrome 19 58
Opsoclonus-Myoclonus-Ataxia Syndrome 19 58
Paraneoplastic Opsoclonus-Myoclonus 19 58
Dancing Eye-Dancing Feet Syndrome 19 58
Otitis Media, Chronic/recurrent 57 73
Ataxo-Opso-Myoclonus Syndrome 19 58
Dancing Eye Syndrome 19 58
Poma Syndrome 19 58
Oma Syndrome 19 58
Come/rom 57 73
{otitis Media, Susceptibility to} 38
Opsoclonus Myoclonus Syndrome 19
Infectious Otitis Media 71
Opsoclonus Myoclonus 52
Om 73

Characteristics:


Inheritance:

Autosomal dominant 57

Prevelance:

Opsoclonus-Myoclonus Syndrome: <1/1000000 (Europe, United Kingdom) 58

Age Of Onset:

Opsoclonus-Myoclonus Syndrome: Childhood,Infancy 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases


External Ids:

Disease Ontology 11 DOID:10754
OMIM® 57 166760
ICD9CM 34 382.9
MeSH 43 D010033
NCIt 49 C34885
SNOMED-CT 68 65363002
ICD10 31 H66.9 H67 H67.8
MESH via Orphanet 44 D053578
ICD10 via Orphanet 32 G25.3
UMLS via Orphanet 72 C0393626 C1096154 C1721017
Orphanet 58 ORPHA1183
MedGen 40 C1833692
UMLS 71 C0029882 C0393626 C1096154 more

Summaries for Otitis Media

CDC: 2 Ear infections can affect the ear canal or the middle ear. Acute otitis externa (AOE) is the scientific name for an infection of the ear canal, which is also called swimmer's ear. Middle ear infections are called Otitis Media, and there are two types of middle ear infections: Otitis Media with Effusion (OME) occurs when fluid builds up in the middle ear without pain, pus, fever, or other signs and symptoms of infection. Acute Otitis Media (AOM) occurs when fluid builds up in the middle ear and is often caused by bacteria, but can also be caused by viruses.

MalaCards based summary: Otitis Media, also known as opsoclonus-myoclonus syndrome, is related to suppurative otitis media and chronic purulent otitis media, and has symptoms including myoclonus and ophthalmoplegia. An important gene associated with Otitis Media is A2ML1 (Alpha-2-Macroglobulin Like 1), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Halofantrine and Montelukast have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and breast, and related phenotypes are sleep disturbance and ataxia

NINDS: 52 Opsoclonus myoclonus is a rare neurological disorder characterized by an unsteady, trembling gait, myoclonus (brief, shock-like muscle spasms), and opsoclonus (irregular, rapid eye movements). Other symptoms may include difficulty speaking, poorly articulated speech, or an inability to speak. A decrease in muscle tone, lethargy, irritability, and malaise (a vague feeling of bodily discomfort) may also be present. Opsoclonus myoclonus may occur in association with tumors or viral infections. It is often seen in children with tumors.

GARD: 19 Opsoclonus-myoclonus syndrome (OMS) is a rare disorder that affects the nervous system. Symptoms include rapid, multi-directional eye movements (opsoclonus), quick, involuntary muscle jerks (myoclonus), uncoordinated movement (ataxia), irritability, and sleep disturbance. The disease may become chronic.

Orphanet: 58 Opsoclonus myoclonus syndrome (OMS) is a rare neuroinflammatory disease of paraneoplastic, parainfectious or idiopathic origin, characterized by opsoclonus, myoclonus, ataxia, and behavioral and sleep disorders.

UniProtKB/Swiss-Prot: 73 An inflammation of the middle ear resulting in earache, fever, hearing disturbance, and vertigo.

Disease Ontology: 11 A otitis which involves inflammation of the middle ear.

Wikipedia: 75 Otitis media is a group of inflammatory diseases of the middle ear. One of the two main types is acute... more...

More information from OMIM: 166760

Related Diseases for Otitis Media

Diseases related to Otitis Media via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1272)
# Related Disease Score Top Affiliating Genes
1 suppurative otitis media 33.6 TLR4 MUC5B MUC5AC FBXO11 A2ML1
2 chronic purulent otitis media 33.5 TLR4 TLR2 MUC5B MUC5AC FBXO11 A2ML1
3 chronic atticoantral disease 33.3 TNF MUC5AC
4 adenoid hypertrophy 32.7 IL6 IL10 CXCL8
5 haemophilus influenzae 32.7 TNF TLR2 LACTB IL1B CXCL8
6 pharyngitis 32.5 TNF TLR2 LACTB IL6 IL1B CXCL8
7 allergic rhinitis 31.9 RNASE3 IL10 CXCL8 CCL11
8 rhinitis 31.9 TNF TLR4 RNASE3 IL6 IL1B IL10
9 middle ear disease 31.9 TNF TLR4 TLR2 MUC5B MUC5AC IL6
10 common cold 31.9 TNF RNASE3 MUC5AC IL6 IL1B IL10
11 meningitis 31.8 TNF TLR4 TLR2 MBL2 LACTB IL6
12 ige responsiveness, atopic 31.7 SPINK5 RNASE3 IL10
13 gastroesophageal reflux 31.7 TNF IL6 IL1B CXCL8 CCL11
14 vasculitis 31.7 TNF MBL2 IL6 IL1B IL10 CXCL8
15 exanthem 31.6 TNF IL6 IL1B IL10 CXCL8
16 viral infectious disease 31.6 TNF TLR4 TLR2 MBL2 IL6 IL1B
17 diarrhea 31.6 TNF TLR4 IL6 IL1B IL10 CXCL8
18 cartilage disease 31.5 TNF IL6 IL1B
19 conjunctivitis 31.4 TNF TLR4 RNASE3 IL6 IL10 CXCL8
20 tonsillitis 31.4 TNF TLR4 TLR2 MBL2 LACTB IL6
21 chlamydia 31.4 TNF TLR4 TLR2 MBL2 IL6 IL1B
22 allergic disease 31.4 TNF RNASE3 IL6 IL1B IL10 CXCL8
23 bacterial meningitis 31.4 TNF TLR4 TLR2 LACTB IL1B IL10
24 apnea, obstructive sleep 31.4 TNF IL6 IL1B IL10 CXCL8
25 osteomyelitis 31.4 TNF TLR4 TLR2 IL6 IL1B IL10
26 cellulitis 31.3 TNF RNASE3 LACTB IL6 IL1B CXCL8
27 encephalitis 31.3 TNF TLR2 IL6 IL1B IL10 CXCL8
28 scarlet fever 31.3 TNF IL6 IL1B
29 hypereosinophilic syndrome 31.3 RNASE3 IL10 CXCL8 CCL11
30 food allergy 31.2 TNF RNASE3 IL10 CXCL8 CCL11
31 pneumonia 31.2 TNF TLR4 TLR2 MUC5B MBL2 LACTB
32 asthma 31.2 TNF TLR4 TLR2 SPINK5 RNASE3 MUC5B
33 measles 31.2 TLR4 TLR2 IL6 IL1B
34 dental caries 31.2 MUC5B MBL2 IL6 IL1B CD79A
35 meningoencephalitis 31.1 TNF IL6 IL1B IL10 CD79A
36 hepatitis a 31.1 TNF TLR4 IL1B IL10
37 tetanus 31.1 TNF IL6 IL1B IL10 CD79A
38 dermatitis 31.1 TNF SPINK5 RNASE3 IL6 IL1B IL10
39 extrapulmonary tuberculosis 31.1 TNF TLR2 IL6 IL1B IL10 CXCL8
40 chickenpox 31.1 TNF IL6 IL1B IL10
41 respiratory failure 31.1 TNF TLR4 RNASE3 MUC5AC IL6 IL1B
42 speech and communication disorders 31.1 TNF IL6 IL1B IL10
43 intracranial hypertension 31.1 TNF IL6 IL1B
44 bronchitis 31.1 TNF TLR4 TLR2 RNASE3 LACTB IL6
45 septic arthritis 31.1 TNF TLR2 IL6 IL1B IL10 CXCL8
46 mucositis 31.1 TLR4 IL1B IL10
47 churg-strauss syndrome 31.1 TNF RNASE3 IL1B IL10 CXCL8 CCL11
48 sleep apnea 31.1 TNF IL6 IL1B IL10 CXCL8
49 aspergillosis 31.0 TNF TLR4 TLR2 MBL2 IL6 IL1B
50 bacterial conjunctivitis 31.0 TNF IL6 IL1B IL10 CXCL8

Comorbidity relations with Otitis Media via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Cholesteatoma of Middle Ear Deficiency Anemia
Heart Disease Hypertension, Essential
Labyrinthitis Mastoiditis
Otitis Externa Pneumococcal Meningitis

Graphical network of the top 20 diseases related to Otitis Media:



Diseases related to Otitis Media

Symptoms & Phenotypes for Otitis Media

Human phenotypes related to Otitis Media:

58 30 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sleep disturbance 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002360
2 ataxia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001251
3 opsoclonus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0010543
4 cognitive impairment 58 30 Frequent (33%) Frequent (79-30%)
HP:0100543
5 irritability 58 30 Frequent (33%) Frequent (79-30%)
HP:0000737
6 vertigo 58 30 Frequent (33%) Frequent (79-30%)
HP:0002321
7 neuroblastoma 58 30 Frequent (33%) Frequent (79-30%)
HP:0003006
8 limb myoclonus 58 30 Frequent (33%) Frequent (79-30%)
HP:0045084
9 melanoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002861
10 breast carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003002
11 encephalopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001298
12 rigidity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002063
13 small cell lung carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030357
14 chronic infection 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031035
15 autoimmune antibody positivity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030057
16 ovarian teratoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012226
17 behavioral abnormality 58 Frequent (79-30%)
18 myoclonus 58 Very frequent (99-80%)
19 recurrent otitis media 30 HP:0000403
20 neoplasm 58 Frequent (79-30%)
21 neoplasm of the lung 58 Occasional (29-5%)
22 abnormal saccadic eye movements 58 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Head And Neck Ears:
otitis media

Clinical features from OMIM®:

166760 (Updated 08-Dec-2022)

UMLS symptoms related to Otitis Media:


myoclonus; ophthalmoplegia

MGI Mouse Phenotypes related to Otitis Media:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 CD79A FBXO11 IL10 IL1B IL6 LACTB
2 immune system MP:0005387 10.07 CCL11 CD79A FBXO11 IL10 IL1B IL6
3 neoplasm MP:0002006 9.95 CD79A IL10 IL1B IL6 TLR2 TLR4
4 digestive/alimentary MP:0005381 9.92 FBXO11 IL10 IL6 MUC5AC SCNN1B TLR2
5 respiratory system MP:0005388 9.76 CCL11 IL10 IL6 MUC5B SCNN1B TLR2
6 skeleton MP:0005390 9.7 FBXO11 IL10 IL1B IL6 LACTB MBL2
7 hematopoietic system MP:0005397 9.4 CCL11 CD79A FBXO11 IL10 IL1B IL6

Drugs & Therapeutics for Otitis Media

Drugs for Otitis Media (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Halofantrine Approved Phase 4 69756-53-2 37393
2
Montelukast Approved Phase 4 158966-92-8 5281040
3
Azithromycin Approved Phase 4 83905-01-5 447043
4
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
5
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Cetirizine Approved Phase 4 83881-51-0 2678
8
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
9
Levocetirizine Approved Phase 4 130018-77-8 1549000
10
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
11
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
13
Phenylephrine Approved Phase 4 59-42-7 6041
14
Cefpodoxime Approved, Vet_approved Phase 4 82619-04-3, 80210-62-4 6335986
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
16
Histamine Approved, Investigational Phase 4 51-45-6 774
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
18
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
19
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
20
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
21 Strawberry Approved Phase 4
22
Cefdinir Approved Phase 4 91832-40-5 6915944
23
Aluminium phosphate Approved, Investigational Phase 4 7784-30-7
24
Morphine Approved, Investigational Phase 4 57-27-2 5288826
25
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
26
Ofloxacin Approved Phase 4 82419-36-1 4583
27
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
28
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
32 Anesthetics Phase 4
33 Leukotriene Antagonists Phase 4
34 Anti-Asthmatic Agents Phase 4
35 Anti-Ulcer Agents Phase 4
36 Antacids Phase 4
37 Proton Pump Inhibitors Phase 4
38 Cardiotonic Agents Phase 4
39
Cefpodoxime proxetil Phase 4 2645
40 Adrenergic alpha-Agonists Phase 4
41 Adrenergic Agonists Phase 4
42 Adrenergic Agents Phase 4
43 Anti-Allergic Agents Phase 4
44 Vasoconstrictor Agents Phase 4
45
Histamine phosphate Phase 4 51-74-1 134614
46 Histamine H1 Antagonists, Non-Sedating Phase 4
47 Histamine H1 Antagonists Phase 4
48
Methylprednisolone Acetate Phase 4 584547
49 Histamine Antagonists Phase 4
50 Mydriatics Phase 4

Interventional clinical trials:

(show top 50) (show all 259)
# Name Status NCT ID Phase Drugs
1 The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children Unknown status NCT00393159 Phase 4
2 Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children Unknown status NCT00299455 Phase 4 amoxicillin-clavulanate;Placebo
3 A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children Completed NCT00189462 Phase 4 Montelukast;Placebo
4 Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial. Completed NCT00539149 Phase 4 Amoxycillin;Placebo equivalent to amoxycillin
5 Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant Completed NCT03590912 Phase 4 Mometasone 50 Mcg/Inh Nasal Spray;Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%);Steroid Drug (prednisolone)
6 Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study Completed NCT01082029 Phase 4 Lansoprazole;Placebo
7 Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM) Completed NCT00377260 Phase 4 amoxicillin-clavulanate;Placebo
8 A Multicenter, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 in Children With Acute Otitis Media (AOM) in India Completed NCT04600752 Phase 4 Augmentin (ES)-600
9 Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®) Completed NCT00419380 Phase 4 dornase alfa (Pulmozyme®)
10 A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media Completed NCT00645112 Phase 4 cefdinir (Omnicef);azithromycin
11 A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media Completed NCT00644943 Phase 4 cefdinir (Omnicef);amoxicillin
12 Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes Completed NCT01244126 Phase 4 Intranasal fentanyl;morphine IM;IV morphine
13 Clinical Trial for the Assessment of Delayed Antibiotic Treatment in the Non-complicated Acute Respiratory Tract Infections in Pediatric (Study DAP-Pediatrics) Completed NCT01800747 Phase 4
14 Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections. Completed NCT01735084 Phase 4
15 A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes Completed NCT01174849 Phase 4 Synflorix;Prevenar13;COMBO
16 Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children: A Randomized Controlled Trial Completed NCT02935374 Phase 4 Amoxicillin;Amoxicillin-Potassium Clavulanate;Macrolide
17 Does the Use of Topical Otic Drops at the Time of Tympanostomy Tube Placement Improve Outcomes When no Middle Ear Effusion is Present at the Time of Surgery Recruiting NCT03655665 Phase 4 Ofloxacin otic solution
18 Prospective, Randomized, Allocation-Concealed, Blinded Study Designed to Compare Ketorolac Sublingual and Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children Recruiting NCT02653742 Phase 4 Ketorolac;Fentanyl
19 Otiprio Versus Ciprodex to Reduce Tympanostomy Tube Failure Withdrawn NCT03347461 Phase 4 Otiprio;Ciprodex
20 N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media Withdrawn NCT00956748 Phase 4 Ciprodex;Ciprodex and 2% NAC
21 PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease Unknown status NCT00310349 Phase 3
22 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children Unknown status NCT01619462 Phase 3
23 A Randomized Control Study of the Outcomes of Mastoidotympanoplasty Versus Tympanoplasty in Quiescent Tubotympanic Otitis Media Unknown status NCT00271778 Phase 3
24 Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays: a Randomized Placebo-controlled Study Completed NCT00279916 Phase 3 Triamcinolone acetonide nasal spray;Placebo nasal spray
25 A Prospective, Single-arm, Multicenter Study to Evaluate Effectiveness and Safety of Tympanostomy Tube Placement Using the Tula Iontophoresis and Tube Delivery Systems for Children in an Office Setting. Completed NCT03323736 Phase 3
26 Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion Completed NCT02432105 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
27 Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion Completed NCT02436304 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
28 A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media Completed NCT01202578 Phase 2, Phase 3
29 Effects of 100% Medical Grade Manuka Honey on Re-epithelialization Post Tympanoplasty in the Case of Mucosal Type Chronic Suppurative Otitis Media (CSOM) - A Prospective Double-blinded Randomized Controlled Trial Completed NCT05605262 Phase 2, Phase 3 Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey
30 Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement Completed NCT01949155 Phase 3 OTO-201;Sham
31 Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement Completed NCT01949142 Phase 3 OTO-201;Sham
32 PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease Completed NCT00714064 Phase 3
33 Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children Completed NCT02541760 Phase 3 Monteleukast;Mometasone
34 Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry Completed NCT01244581 Phase 3 Amoxicillin-clavulanate;Placebo
35 Safety and Efficacy of Sinuclean Nebules 45 (Class 1 Medical Device) in the Treatment of Pediatric Exudative Otitis Media, Randomized, Double Blind, Comparative, Parallel Study Completed NCT02858388 Phase 3
36 Video, Ear Infections & Antibiotic Stewardship: Knowledge Translation Upon Emergency Department Discharge Completed NCT02703389 Phase 3
37 A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years Completed NCT02044341 Phase 3 AR01;Glycerin ear drops
38 Efficacy Trial in Finnish Children of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Pneumococcal Serotypes in the Vaccines Completed NCT00378417 Phase 3
39 An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media Completed NCT00645203 Phase 2, Phase 3 cefdinir
40 Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media Completed NCT02630992 Phase 3 Amoxicillin-Clavulanate potassium
41 Evaluation of the Safety, Efficacy, Pharmacokinetics, and Acceptability of HMR3647 20 mg/kg qd for 5 Days With Acute Otitis Media (AOM) in Children (Multicenter, Open Label, Non Comparative Study) Completed NCT00638534 Phase 3 Telithromycin (HMR3647)
42 An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes Completed NCT02600559 Phase 3 OTO-201 (ciprofloxacin)
43 A Pilot, Multicenter, Open Label, Non Comparative Study of the Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children With Tympanostomy Tubes Completed NCT00781521 Phase 3 ofloxacin otic solution 0.3%
44 A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Amoxicillin/Clavulanate Potassium (Augmentin ES-600 Trademark) for the Treatment of Acute Otitis Media in Children Undergoing Diagnostic Tympanocentesis Completed NCT00643292 Phase 3 amoxicillin/clavulanate postassium (Augmentin ES-600);azithromycin SR
45 A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media Completed NCT00051753 Phase 3 levofloxacin; amoxicillin/clavulanate
46 An Open-Label Study of Levofloxacin to Evaluate Bacteriologic Outcome in the Treatment of Children Who Are at Risk for Acute Otitis Media That is Difficult to Treat Completed NCT00044473 Phase 3 levofloxacin
47 Comparison of Treatment Satisfaction and Treatment Adherence of a Novel Application Form "Dose Sipping Technology" (DST) of Oral Clarithromycin vs. Clarithromycin Syrup in Children Suffering From Acute Otitis Media, Tonsillitis, Pharyngitis, or Acute Bacterial Bronchitis (DoSe iT) Completed NCT04016051 Phase 3 Clarithromycin DST (125 mg);Clarithromycin DST (187.5 mg);Clarithromycin DST (250 mg);Clarithromycin Syrup (125 mg);Clarithromycin Syrup (187.5 mg);Clarithromycin Syrup (250 mg)
48 Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT) Completed NCT00579189 Phase 3 Moxidex otic solution;Moxifloxacin otic solution
49 Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Group Comparison for Superiority Completed NCT02345447 Phase 3 Herbal-based medication;Placebo
50 Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Parallel-Designed Evaluation to Assess Safety and Efficacy of Topical Benzocaine for Treatment of Pain Associated With Acute Otitis Media in Children Ages 5 to 12 Years Completed NCT03116737 Phase 3 Benzocaine Otic Solution;Placebo

Search NIH Clinical Center for Otitis Media

Inferred drug relations via UMLS 71 / NDF-RT 50 :


acetyl sulfisoxazole
Antipyrine
Benzocaine
BENZOCAINE PWDR
CEFTIBUTEN DIHYDRATE
Sulfisoxazole
Sulfisoxazole Diolamine

Cochrane evidence based reviews: otitis media

Genetic Tests for Otitis Media

Genetic tests related to Otitis Media:

# Genetic test Affiliating Genes
1 Otitis Media, Susceptibility to 28 A2ML1
2 Otitis Media 28

Anatomical Context for Otitis Media

Organs/tissues related to Otitis Media:

MalaCards : Eye, Bone, Breast, Lung, Tonsil, Brain, Neutrophil

Publications for Otitis Media

Articles related to Otitis Media:

(show top 50) (show all 22913)
# Title Authors PMID Year
1
Genetic and Environmental Determinants of Otitis Media in an Indigenous Filipino Population. 62 57 5
27484237 2016
2
Otitis media susceptibility and shifts in the head and neck microbiome due to SPINK5 variants. 62 5
32709676 2021
3
A2ML1 and otitis media: novel variants, differential expression, and relevant pathways. 62 5
31009165 2019
4
Rare A2ML1 variants confer susceptibility to otitis media. 62 57
26121085 2015
5
Eya4-deficient mice are a model for heritable otitis media. 62 57
18219393 2008
6
Chronic and recurrent otitis media: a genome scan for susceptibility loci. 62 57
15514890 2004
7
The heritability of otitis media: a twin and triplet study. 62 57
10591333 1999
8
Susceptibility to otitis media: strong evidence that genetics plays a role. 62 57
10591340 1999
9
Familial predisposition for otitis media in Apache Indians at Canyon Day, Arizona. 62 57
3569876 1987
10
Mucin gene polymorphisms in otitis media patients. 53 62
19718741 2010
11
[Evaluation of percentage of lymphocytes B with expression of co-receptors CD 40, CD22 and CD72 in hypertrophied adenoid at children with otitis media with effusion]. 53 62
20198985 2009
12
Glucocorticoids inhibit nontypeable Haemophilus influenzae-induced MUC5AC mucin expression via MAPK phosphatase-1-dependent inhibition of p38 MAPK. 53 62
18957283 2008
13
Toll-like receptors 2 and 4 and their mutations in patients with otitis media and middle ear effusion. 53 62
19434266 2008
14
Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome. 53 62
18991196 2008
15
Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. 53 62
18008233 2007
16
Association of CD14 promoter polymorphism with otitis media and pneumococcal vaccine responses. 53 62
16893989 2006
17
Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. 53 62
16750996 2006
18
[The measuring of ECP and IgE in middle ear effusion of patients with otitis media of effusion]. 53 62
16883790 2006
19
Total serum IgE and IgE antibodies specific to house dust mite found in two aged-matched cohorts of children with and without otitis media with effusion. 53 62
16620332 2006
20
Up-regulation of MUC5AC and MUC5B mucin genes in nasopharyngeal respiratory mucosa and selective up-regulation of MUC5B in middle ear in pediatric otitis media with effusion. 53 62
16540890 2006
21
Role of mannose-binding lectin (MBL2) genotyping in predicting the risk of recurrent otitis media (rOM). 53 62
16893079 2006
22
Childhood levels of immunoglobulins and mannan-binding lectin in relation to infections and allergy. 53 62
15882439 2005
23
Immunological status in the aetiology of recurrent otitis media with effusion: serum immunoglobulin levels, functional mannose-binding lectin and Fc receptor polymorphisms for IgG. 53 62
15742161 2005
24
Immunological parameters in girls with Turner syndrome. 53 62
15563731 2004
25
IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. 53 62
12737295 2003
26
Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. 53 62
11867630 2002
27
Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. 53 62
11163480 2000
28
Increased expression of major basic protein (MBP) and interleukin-5(IL-5) in middle ear biopsy specimens from atopic patients with persistent otitis media with effusion. 53 62
11077335 2000
29
[Immunology in the medical practice. XXVII. Mannose-binding lectin, an important link for nonspecific or hereditary immune reaction]. 53 62
10897301 2000
30
Eosinophils and neutrophils in biopsies from the middle ear of atopic children with otitis media with effusion. 53 62
10669113 1999
31
The influence of karyotype on the auricle, otitis media and hearing in Turner syndrome. 53 62
10575123 1999
32
Evidence of possible localized specific immunoglobulin E production in middle ear fluid as demonstrated by ELISA testing. 53 62
10471862 1999
33
Microbial factors leading to recurrent upper respiratory tract infections. 53 62
9727652 1998
34
Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. 53 62
9613746 1998
35
Eosinophil cationic protein in mucosal biopsies from patients with allergy and otitis media with effusion. 53 62
9230321 1997
36
Association of otitis media with effusion and allergy as demonstrated by intradermal skin testing and eosinophil cationic protein levels in both middle ear effusions and mucosal biopsies. 53 62
8822719 1996
37
Levels of eosinophil cationic protein and myeloperoxidase from chronic middle ear effusion in patients with allergy and/or acute infection. 53 62
8643262 1996
38
Mannan-binding protein--levels in plasma and upper-airways secretions and frequency of genotypes in children with recurrence of otitis media. 53 62
8403525 1993
39
The presence of eosinophil cationic protein in middle ear effusion. 53 62
8516010 1993
40
Correlation between serum immunoglobulin A concentrations and allergic manifestations in infants. 53 62
1625088 1992
41
Sulbactam/ampicillin in the treatment of otitis and sinusitis. 53 62
2060691 1991
42
The role of bacterial adherence in otitis media with effusion. 53 62
2206498 1990
43
Prospective study about the incidence of B lactamase producing bacteriae in otitis media in the population of the emergency room of the University Pediatric Hospital. 53 62
2375816 1990
44
Warm-season temperatures and emergency department visits among children with health insurance. 62
36337257 2023
45
Unified Airway Disease: Future Directions. 62
36410990 2023
46
Epidemiological characteristics and antibiotic resistance mechanisms of Streptococcus pneumoniae: An updated review. 62
36244081 2023
47
Role of mastoid pneumatization in predicting tympanoplasty results: Will it have the same importance in different age groups? 62
36334419 2023
48
Otomycosis caused by the cryptic and emerging species Aspergillus sydowii: two case reports. 62
36382573 2022
49
Combined Electric acoustic stimulation in a patient with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis. 62
33962817 2022
50
Outpatient Antibiotic Prescribing for 357,390 Children With Otitis Media. 62
36102742 2022

Variations for Otitis Media

ClinVar genetic disease variations for Otitis Media:

5 (show all 28)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 A2ML1 NM_144670.6(A2ML1):c.4061+1G>C SNV Pathogenic
Likely Pathogenic
617554 rs202067416 GRCh37: 12:9020954-9020954
GRCh38: 12:8868358-8868358
2 SDHA NM_004168.4(SDHA):c.1534C>T (p.Arg512Ter) SNV Pathogenic
371805 rs748089700 GRCh37: 5:240574-240574
GRCh38: 5:240459-240459
3 SPINK5 NM_006846.4(SPINK5):c.1682A>G (p.Glu561Gly) SNV Likely Pathogenic
918078 rs1753847242 GRCh37: 5:147488390-147488390
GRCh38: 5:148108827-148108827
4 SCNN1B NM_000336.3(SCNN1B):c.1609C>T (p.Leu537Phe) SNV Likely Pathogenic
1707413 GRCh37: 16:23391808-23391808
GRCh38: 16:23380487-23380487
5 A2ML1 NM_144670.6(A2ML1):c.2478_2485dup (p.Ser829fs) DUP Risk Factor
217306 rs863224951 GRCh37: 12:9004818-9004819
GRCh38: 12:8852222-8852223
6 A2ML1 NM_144670.6(A2ML1):c.10C>T (p.Gln4Ter) SNV Likely Pathogenic
Likely Pathogenic
617555 rs1409944554 GRCh37: 12:8975257-8975257
GRCh38: 12:8822661-8822661
7 A2ML1 NM_144670.6(A2ML1):c.1308A>C (p.Gln436His) SNV Uncertain Significance
Uncertain Significance
617557 rs780743143 GRCh37: 12:8995789-8995789
GRCh38: 12:8843193-8843193
8 A2ML1 NM_144670.6(A2ML1):c.1683G>C (p.Gln561His) SNV Uncertain Significance
Uncertain Significance
626340 rs1565476223 GRCh37: 12:8998818-8998818
GRCh38: 12:8846222-8846222
9 A2ML1 NM_144670.6(A2ML1):c.2012T>C (p.Leu671Pro) SNV Uncertain Significance
Uncertain Significance
617558 rs1465018225 GRCh37: 12:9001494-9001494
GRCh38: 12:8848898-8848898
10 A2ML1 NM_144670.6(A2ML1):c.2228C>T (p.Pro743Leu) SNV Uncertain Significance
Uncertain Significance
626342 rs1565479896 GRCh37: 12:9002864-9002864
GRCh38: 12:8850268-8850268
11 A2ML1 NM_144670.6(A2ML1):c.2329G>A (p.Gly777Arg) SNV Uncertain Significance
Uncertain Significance
617559 rs201288888 GRCh37: 12:9004474-9004474
GRCh38: 12:8851878-8851878
12 A2ML1 NM_144670.6(A2ML1):c.2545G>T (p.Asp849Tyr) SNV Uncertain Significance
Uncertain Significance
626343 rs1408810942 GRCh37: 12:9004887-9004887
GRCh38: 12:8852291-8852291
13 A2ML1 NM_144670.6(A2ML1):c.2971G>C (p.Ala991Pro) SNV Uncertain Significance
Uncertain Significance
626344 rs1565484901 GRCh37: 12:9009882-9009882
GRCh38: 12:8857286-8857286
14 A2ML1 NM_144670.6(A2ML1):c.3491C>T (p.Ala1164Val) SNV Uncertain Significance
Uncertain Significance
626345 rs1565487941 GRCh37: 12:9013882-9013882
GRCh38: 12:8861286-8861286
15 A2ML1 NM_144670.6(A2ML1):c.971-8C>T SNV Uncertain Significance
Uncertain Significance
617556 rs780868782 GRCh37: 12:8991701-8991701
GRCh38: 12:8839105-8839105
16 A2ML1 NM_144670.6(A2ML1):c.2677C>T (p.Arg893Ter) SNV Uncertain Significance
217310 rs199651558 GRCh37: 12:9006810-9006810
GRCh38: 12:8854214-8854214
17 A2ML1 NM_144670.6(A2ML1):c.2197T>C (p.Phe733Leu) SNV Uncertain Significance
Uncertain Significance
384690 rs117213221 GRCh37: 12:9002833-9002833
GRCh38: 12:8850237-8850237
18 A2ML1 NM_144670.6(A2ML1):c.4061+1G>A SNV Uncertain Significance
696412 rs202067416 GRCh37: 12:9020954-9020954
GRCh38: 12:8868358-8868358
19 PLG NM_000301.5(PLG):c.782G>A (p.Arg261His) SNV Uncertain Significance
692201 rs4252187 GRCh37: 6:161137790-161137790
GRCh38: 6:160716758-160716758
20 PLG NM_000301.5(PLG):c.2045T>A (p.Ile682Asn) SNV Uncertain Significance
692203 rs147175166 GRCh37: 6:161162369-161162369
GRCh38: 6:160741337-160741337
21 PLG NM_000301.5(PLG):c.1481C>T (p.Ala494Val) SNV Uncertain Significance
692204 rs4252128 GRCh37: 6:161152819-161152819
GRCh38: 6:160731787-160731787
22 A2ML1 NM_144670.6(A2ML1):c.3676_3677del (p.Ala1226fs) DEL Uncertain Significance
413822 rs144686314 GRCh37: 12:9016563-9016564
GRCh38: 12:8863967-8863968
23 A2ML1 NM_144670.6(A2ML1):c.164C>T (p.Thr55Ile) SNV Uncertain Significance
Uncertain Significance
626339 rs999028234 GRCh37: 12:8975879-8975879
GRCh38: 12:8823283-8823283
24 A2ML1 NM_144670.6(A2ML1):c.2189G>A (p.Arg730His) SNV Uncertain Significance
Uncertain Significance
626341 rs200346409 GRCh37: 12:9002825-9002825
GRCh38: 12:8850229-8850229
25 A2ML1 NM_144670.6(A2ML1):c.2713-8C>A SNV Uncertain Significance
Uncertain Significance
241896 rs184386564 GRCh37: 12:9007368-9007368
GRCh38: 12:8854772-8854772
26 PLG NM_000301.5(PLG):c.112A>G (p.Lys38Glu) SNV Benign
13583 rs73015965 GRCh37: 6:161127501-161127501
GRCh38: 6:160706469-160706469
27 A2ML1 NM_144670.6(A2ML1):c.3364C>T (p.Arg1122Trp) SNV Benign
384669 rs1860967 GRCh37: 12:9013755-9013755
GRCh38: 12:8861159-8861159
28 PLG NM_000301.5(PLG):c.1414G>A (p.Asp472Asn) SNV Benign
692202 rs4252125 GRCh37: 6:161152240-161152240
GRCh38: 6:160731208-160731208

Expression for Otitis Media

LifeMap Discovery
Genes differentially expressed in tissues of Otitis Media patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PNLIPRP3 pancreatic lipase related protein 3 Blood - 6.47 0.003
2 FAM20A FAM20A golgi associated secretory pathway pseudokinase Blood + 3.09 0.015
Search GEO for disease gene expression data for Otitis Media.

Pathways for Otitis Media

Pathways related to Otitis Media according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CCL11 CD79A CXCL8 FBXO11 IL10 IL1B
2
Show member pathways
13.79 TLR4 TLR2 MUC5B MUC5AC MBL2 IL6
3
Show member pathways
13.42 CCL11 CXCL8 IL10 IL1B IL6 TLR2
4
Show member pathways
12.89 TNF TLR4 TLR2 MBL2 IL6 IL1B
5
Show member pathways
12.71 IL1B IL6 TLR2 TLR4 TNF
6
Show member pathways
12.62 TNF TLR2 MUC5B MUC5AC IL6 IL1B
7 12.59 TNF TLR2 IL1B IL10 CD79A
8
Show member pathways
12.57 TNF TLR4 TLR2 IL6 IL1B CXCL8
9
Show member pathways
12.35 TNF TLR4 IL6 IL1B CXCL8
10
Show member pathways
12.31 CCL11 CXCL8 IL1B IL6 TLR2 TLR4
11
Show member pathways
12.3 TNF TLR2 MUC5B MUC5AC IL6 CXCL8
12 12.23 TNF IL6 IL1B IL10 CXCL8
13 12.2 TNF TLR4 TLR2 IL6
14 12.12 TNF IL6 IL1B IL10
15 12.06 CXCL8 IL1B IL6 TLR4 TNF
16 12.02 TNF IL6 IL10 CD79A
17 11.92 TNF IL1B IL10 CXCL8
18
Show member pathways
11.91 TLR4 TLR2 IL6 IL1B
19
Show member pathways
11.85 TLR4 IL6 CXCL8
20 11.81 TNF IL6 IL1B IL10
21 11.78 TNF IL1B IL10
22 11.78 CXCL8 IL1B IL6 TLR4 TNF
23 11.77 TNF IL6 IL1B IL10 CXCL8 CCL11
24 11.75 TLR4 IL6 IL10
25
Show member pathways
11.73 TNF IL6 IL1B CXCL8
26 11.73 TNF TLR4 IL6 IL10 CD79A
27 11.71 IL6 IL10 CXCL8
28 11.65 TNF TLR4 IL6 IL10 CXCL8
29 11.63 TNF TLR4 IL6 CXCL8
30
Show member pathways
11.63 TNF TLR4 TLR2 IL6 IL1B IL10
31 11.62 TNF TLR4 IL6 IL1B IL10
32 11.59 TNF TLR4 TLR2 IL1B
33 11.57 TNF IL10 CXCL8
34
Show member pathways
11.57 TNF TLR4 TLR2 IL6 IL10
35 11.51 TNF IL6 IL1B
36 11.49 TNF TLR4 IL6
37 11.39 TNF IL6 IL1B IL10 CXCL8
38 11.36 TNF IL6 IL1B CXCL8
39 11.35 TNF IL6 IL1B
40 11.34 TNF IL6 IL1B IL10
41 11.32 TNF IL6 IL1B CXCL8
42 11.29 TNF IL6 IL10 CXCL8
43 11.12 TLR4 IL6 IL1B IL10
44 11.1 CXCL8 IL6 TNF
45 11.04 TNF IL6 IL1B IL10 CXCL8 CCL11
46 10.9 TNF TLR4 IL6 IL1B IL10
47 10.9 TNF MUC5B IL6 IL1B CXCL8 CCL11
48 10.78 IL6 IL1B
49 10.7 IL6 CXCL8
50 10.65 TLR4 TLR2

GO Terms for Otitis Media

Cellular components related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10 A2ML1 CCL11 CXCL8 IL10 IL1B IL6
2 extracellular region GO:0005576 9.64 TNF SPINK5 RNASE3 MUC5B MUC5AC MBL2

Biological processes related to Otitis Media according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.38 TNF TLR2 IL6 IL1B IL10 CXCL8
2 inflammatory response GO:0006954 10.36 CCL11 CXCL8 IL1B IL6 TLR2 TLR4
3 positive regulation of DNA-binding transcription factor activity GO:0051091 10.25 TNF IL6 IL1B IL10
4 defense response to bacterium GO:0042742 10.23 TNF TLR4 RNASE3 MBL2 IL10
5 positive regulation of inflammatory response GO:0050729 10.23 TNF TLR4 TLR2 IL1B
6 cellular response to type II interferon GO:0071346 10.21 CCL11 TLR2 TLR4 TNF
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.21 TNF TLR4 TLR2 IL6 IL1B
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.17 IL1B TLR2 TLR4 TNF
9 regulation of insulin secretion GO:0050796 10.16 TNF IL6 IL1B
10 response to activity GO:0014823 10.15 TNF IL6 IL10
11 positive regulation of nitric oxide biosynthetic process GO:0045429 10.14 TNF TLR4 IL1B
12 positive regulation of interleukin-10 production GO:0032733 10.14 IL6 TLR2 TLR4
13 positive regulation of interleukin-6 production GO:0032755 10.13 IL1B IL6 TLR2 TLR4 TNF
14 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.12 TNF IL6 IL10
15 cellular response to lipopolysaccharide GO:0071222 10.11 TNF TLR4 IL6 IL1B IL10 CXCL8
16 liver regeneration GO:0097421 10.1 TNF IL6 IL10
17 response to lipopolysaccharide GO:0032496 10.09 TNF TLR4 TLR2 IL1B IL10
18 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.08 TNF TLR4 IL6
19 B cell proliferation GO:0042100 10.07 TLR4 IL10 CD79A
20 lipopolysaccharide-mediated signaling pathway GO:0031663 10.06 TNF TLR4 TLR2 IL1B
21 immune response GO:0006955 10.06 TNF TLR4 TLR2 IL6 IL1B IL10
22 positive regulation of glial cell proliferation GO:0060252 10.05 TNF IL6 IL1B
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.01 TNF IL1B IL10
24 positive regulation of oxidative stress-induced neuron death GO:1903223 9.97 TNF TLR4
25 negative regulation of cytokine production involved in immune response GO:0002719 9.97 TNF IL10
26 positive regulation of fever generation GO:0031622 9.96 TNF IL1B
27 positive regulation of neuroinflammatory response GO:0150078 9.95 TNF IL6 IL1B
28 sequestering of triglyceride GO:0030730 9.94 IL1B TNF
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.92 TNF IL1B
30 positive regulation of matrix metallopeptidase secretion GO:1904466 9.9 TLR4 TLR2
31 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.89 TLR4 TLR2
32 response to molecule of bacterial origin GO:0002237 9.89 TLR2 IL10 CXCL8
33 chronic inflammatory response to antigenic stimulus GO:0002439 9.88 TNF IL10
34 vascular endothelial growth factor production GO:0010573 9.88 TNF IL6 IL1B
35 negative regulation of neurogenesis GO:0050768 9.86 CCL11 IL1B IL6 TNF
36 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR4 TLR2 IL6 IL1B
37 defense response to Gram-positive bacterium GO:0050830 9.73 TNF TLR2 RNASE3 MBL2 IL6 IL1B
38 response to external stimulus GO:0009605 9.7 TLR4 TLR2 CXCL8
39 positive regulation of chemokine production GO:0032722 9.28 TNF TLR4 TLR2 IL6 IL1B

Molecular functions related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide immune receptor activity GO:0001875 9.46 TLR4 TLR2
2 lipopolysaccharide binding GO:0001530 9.43 TLR4 TLR2 RNASE3
3 cytokine activity GO:0005125 9.32 TNF IL6 IL1B IL10 CXCL8 CCL11

Sources for Otitis Media

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....